Table 4. New targeted drugs that may... | American Society of Hematology

Table 4.

New targeted drugs that may counteract anemia in older patients

Drug	Lexaptepid-pegol NOX-94H	PRS-080	RO62	CSJ137	H5F9-AM8
Target	Hepcidin	Hepcidin	BMP6	BMP6?	HJV (RGMc)
Modality	PEGylated Spiegelmer	Anticalin scaffold	Engineered heparins	IgG1	Unclear
Mechanism	Hepcidin binding	Hepcidin binding	BMP6 binding	BMP6 binding (?)	Unclear
Indications	MM, CKD, cancer	CKD	Unknown	Functional iron deficiency by CKD	CKD likely
Phase	Phase 2	Phase 1	Discovery	Phase 1/2	Phase 1 (?)
Company	Noxxon	Pieris	Glycolsplit heparins	Novartis	AbbVie

Drug	Lexaptepid-pegol NOX-94H	PRS-080	RO62	CSJ137	H5F9-AM8
Target	Hepcidin	Hepcidin	BMP6	BMP6?	HJV (RGMc)
Modality	PEGylated Spiegelmer	Anticalin scaffold	Engineered heparins	IgG1	Unclear
Mechanism	Hepcidin binding	Hepcidin binding	BMP6 binding	BMP6 binding (?)	Unclear
Indications	MM, CKD, cancer	CKD	Unknown	Functional iron deficiency by CKD	CKD likely
Phase	Phase 2	Phase 1	Discovery	Phase 1/2	Phase 1 (?)
Company	Noxxon	Pieris	Glycolsplit heparins	Novartis	AbbVie

IgG1, immunoglobulin G1; MM, multiple myeloma; PEG, polyethylene glycol.